je.st
news
Tag: isis pharmaceuticals
Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA
2014-11-25 16:58:52| Biotech - Topix.net
Isis Pharmaceuticals, Inc. announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy . SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness.
Tags: with
study
children
phase
AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
2014-11-13 19:01:24| Biotech - Topix.net
Isis Pharmaceuticals and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively.
Tags: methods
delivery
targeted
pharmaceuticals
Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study
2014-10-10 04:59:10| Biotech - Topix.net
Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy . "ISIS-TTRRx is the most advanced drug in our collaboration with GSK, and aside from KYNAMRO, it is also the furthest advanced in our late-stage clinical pipeline.
Tags: study
million
advance
phase
Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1
2014-06-10 09:16:58| Biotech - Topix.net
Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-DMPKRx.
Tags: type
study
treatment
phase
Isis Pharmaceuticals: - The Best Pipeline in Biotech,' Potential Takeover Target
2014-05-23 21:19:24| Biotech - Topix.net
Shares of Isis Pharmaceuticals have gained 9% to $27.20 at 1:26 p.m. today, easily besting similar biotech companies like Alnylam Pharmaceuticals , which has risen 3.8% to $57.67, and Sarepta Therapeutics , which has advanced 4.1% to $33.88.
Tags: potential
target
biotech
pipeline